All Trials

Phase I, Open-Label Study of Dually Armored Chimeric Antigen Receptor (CAR) T Cells (TmPSMA-02) in Patients With Metastatic Castrate-Resistant Prostate Cancer (mCRPC)

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Men with metastatic castration‑resistant prostate cancer (ECOG 0–1) after at least one standard mCRPC therapy receive fludarabine/cyclophosphamide lymphodepletion followed by a single infusion of autologous PSMA‑targeted CAR T cells (TmPSMA‑02). The CAR uses a humanized J591 scFv with CD2/CD3ζ signaling and dual “armor” (dominant‑negative TGF‑βRII and PD1–CD28 switch receptor) to enhance activity and overcome immunosuppression.

ClinicalTrials.gov ID: NCT06046040

A Phase I, First-in-human, Dose Escalation Study Of [225Ac]-AZD2284 in Patients With Metastatic Castration-Resistant Prostate Cancer

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with metastatic castration-resistant prostate cancer (adenocarcinoma or neuroendocrine variants), ECOG 0–1, are enrolled to receive a STEAP2-targeted theranostic: imaging with radiolabeled AZD2287 (± cold antibody AZD2275 pre-dose) followed by dose-escalated [225Ac]-AZD2284, an actinium-225–labeled anti-STEAP2 monoclonal antibody delivering alpha radiation to STEAP2-expressing tumors. Key exclusions include recent radiopharmaceuticals/therapy and significant comorbidities; outcomes focus on safety, dosimetry, biodistribution, and preliminary antitumor activity.

ClinicalTrials.gov ID: NCT06879041

A Phase 1 Study of Gemcitabine, Nab-Paclitaxel, and Bosentan in Patients With Unresectable Pancreatic Cancer

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Adults with unresectable pancreatic carcinoma eligible for gemcitabine plus nab-paclitaxel receive that regimen with added oral bosentan, a dual endothelin receptor antagonist intended to modulate tumor stroma and perfusion to enhance drug delivery. Key exclusions include significant neuropathy and interacting CYP3A/CYP2C9 drugs; safety, tolerability, and preliminary antitumor activity are assessed across different bosentan lead-in schedules.

ClinicalTrials.gov ID: NCT04158635

Phase I/II Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells Delivered Intraperitoneally for the Management of Platinum Resistant Ovarian Cancer, Mesonephric-like Adenocarcinoma, and Pancreatic Cancer

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with TROP2-positive, platinum-resistant ovarian/peritoneal/fallopian tube cancer, mesonephric-like adenocarcinoma, or pancreatic/ampullary cancer with peritoneal/retroperitoneal disease receive lymphodepleting cyclophosphamide/fludarabine followed by a single intraperitoneal infusion of allogeneic cord blood–derived NK cells engineered with a TROP2-directed CAR and IL-15 for persistence. Designed to assess safety and preliminary efficacy of intraperitoneal TROP2 CAR-NK in heavily pretreated patients without active CNS disease or contraindications to IP therapy.

ClinicalTrials.gov ID: NCT05922930

A Phase 1 Dose Finding Study of the gFOLFOXIRITAX Regimen Using UGT1A1 Genotype-directed Irinotecan With Fluorouracil, Leucovorin, Oxaliplatin and Taxotere in Patients With Untreated Advanced Upper Gastrointestinal Adenocarcinomas: The I-FLOAT Study

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Adults with untreated locally advanced or metastatic upper GI adenocarcinomas (including pancreatic, gastroesophageal, cholangiocarcinoma, gallbladder, ampullary, and select CUP) receive a multi-agent regimen of irinotecan, 5-FU/leucovorin, oxaliplatin, and docetaxel, with irinotecan dose tailored by UGT1A1 genotype. The study assesses safety, tolerability, and preliminary efficacy of this intensive first-line combination in ECOG 0–1 patients.

ClinicalTrials.gov ID: NCT04361708

A Phase 1 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of BL-M05D1 in Subjects With Advanced or Metastatic Solid Tumors

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with unresectable locally advanced or metastatic CLDN18.2-positive solid tumors (e.g., gastric/GEJ, pancreatic, esophageal adenocarcinoma, biliary tract cancers) after prior systemic therapy receive BL-M05D1, an IV CLDN18.2-targeting antibody–drug conjugate linking a cathepsin B–cleavable topoisomerase I inhibitor payload, given every 21 days. Key eligibility includes measurable disease, ECOG 0–1, adequate organ function, and prior appropriate targeted/immunotherapy for actionable biomarkers.

ClinicalTrials.gov ID: NCT07021066

A Phase 2 Study With Combination Chemotherapy (Gemcitabine and Nab-Paclitaxel), Chemokine (C-X-C) Motif Receptor 4 Inhibitor (BL-8040), and Immune Checkpoint Blockade (Cemiplimab) in METastatic Treatment naïve PANCreas Adenocarcinoma

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Metastatic, treatment-naïve PDAC (ECOG 0–1) receiving first-line gemcitabine/nab-paclitaxel plus motixafortide (CXCR4 antagonist to disrupt stroma and enhance immune infiltration) and cemiplimab (PD‑1 inhibitor); requires measurable disease and biopsy-accessible tumor. Excludes prior PDAC therapy, active autoimmune disease requiring treatment, CNS mets, uncontrolled infections/hepatitis/HIV, and significant comorbidity.

ClinicalTrials.gov ID: NCT04543071

A Phase I/Ib Trial of ProAgio, an Anti- αvβ3 Integrin Cytotoxin, in Combination With Gemcitabine and Nab-paclitaxel for Advanced Pancreatic Cancer

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Previously untreated adults with metastatic PDAC (ECOG 0–1) receive ProAgio—an investigational pegylated peptide that targets integrin αvβ3 on cancer‑associated fibroblasts and endothelial cells to induce apoptosis and remodel stroma/vasculature—alone and in combination with standard gemcitabine plus nab‑paclitaxel. Excludes prior gem/nab‑paclitaxel and significant neuropathy, unstable autoimmune/cardiovascular disease, serious infection, or untreated/unstable CNS metastases.

ClinicalTrials.gov ID: NCT06182072

Multi-agent Low Dose Chemotherapy (Gemcitabine, Nab-paclitaxel, Capecitabine, Cisplatin, Irinotecan) Followed by Maintenance Olaparib and Pembrolizumab in Untreated Metastatic Pancreatic Ductal Adenocarcinoma.

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Adults with previously untreated metastatic PDAC (ECOG 0–1) receive low-dose multi-agent induction chemotherapy (gemcitabine, nab-paclitaxel, capecitabine, cisplatin, irinotecan), then transition to maintenance pembrolizumab (anti–PD-1) plus olaparib (PARP inhibitor) with biopsy required and no prior PD-1/PD-L1 or PARP exposure. Designed to test whether PARP inhibition combined with PD-1 blockade can maintain disease control beyond biomarker-restricted subsets following cytotoxic induction.

ClinicalTrials.gov ID: NCT04753879

Phase I/II Study of Anti-CD3 x Anti-EGFR Bispecific Antibody (EGFRBi) Armed Fresh Peripheral Blood Mononuclear Cells (EGFR FPBMC) in Metastatic or Unresectable Pancreatic Cancer

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with unresectable/locally advanced or metastatic pancreatic adenocarcinoma after at least one prior systemic regimen (and prior targeted/immunotherapy when indicated), ECOG 0–1, receive repeated infusions of autologous PBMCs armed ex vivo with an anti-CD3 × anti-EGFR bispecific antibody that redirects T-cell cytotoxicity to EGFR-expressing tumors. Treatment involves 8 weekly infusions followed by 8 biweekly infusions after a second leukapheresis; key exclusions include EGFR mAb hypersensitivity, active infections, and autoimmune disease requiring immunosuppression.

ClinicalTrials.gov ID: NCT06479239